Stabilization of Glomerular Filtration Rate in Advanced Chronic Kidney Disease: A Two-Year Follow-up of a Cohort of Chronic Kidney Disease Patients Stages 4 and 5

Advances in Chronic Kidney Disease

Volumn 14, Issue 1, 2007, Pages 105-112

  Serrano, Andres ^a   Huang, Jie ^a   Ghossein, Cybele ^a   Nishi, Laura ^a   Gangavathi, Anupama ^a   Madhan, Vijayachitra ^a   Ramadugu, Paramesh ^a   Ahya, Shubhada N ^a   Paparello, James ^a   Khosla, Neenoo ^a   Schlueter, William ^a   Batlle, Daniel ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Advanced chronic kidney disease; Anemia; Glomerular filtration rate; Mortality rate; Progression

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; CALCULATION; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DEATH; DIALYSIS; ETHNICITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; COHORT STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 33845753090     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2006.07.009     Document Type: Article

References (37)

1. Brenner B.M., Meyer T.W., and Hostetter T.H. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307 (1982) 652-659
2. Mitch W.E., Walser M., Buffington G.A., et al. A simple method of estimating progression of chronic renal failure. Lancet 2 (1976) 1326-1328
3. Klahr S., Schreiner G., and Ichikawa I. The progression of renal disease. N Engl J Med 318 (1988) 1657-1666
4. Mackenzie H.S., Taal M.W., Luyckx V.A., et al. Adaptation to nephron loss. In: Brenner B.M. (Ed). The Kidney. (ed 6) (2000), WB Saunders, Philadelphia 1901-1942
5. Keith D.S., Nichols G.A., Gullion C.M., et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164 (2004) 659-663
6. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
7. Brenner B.M., Cooper M.E., De Zeeuw D., et al., REENAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
8. Hunsicker L.G., Sharon A., Caggiula A., et al. Modification of diet in renal disease study group. Predictors of the progression of renal disease in the modification of diet in renal disease study. Kidney Int 51 (1997) 1908-1919
9. Collins A.J., Li S., Gilbertson D.T., et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int 64 (2003) 24-31
10. Coresh J., Astor B.C., Greene T., et al. Prevalence of chronic kidney disease and decrease kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 (2003) 1-12
11. Go A., Chertow G., Fan D., et al. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
12. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J kidney Dis 39 suppl 1 (2002) S1-S266
13. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130 (1999) 461-470
14. Mehrotra R., and Nolph K. Treatment of advanced renal failure: Low protein diets or timely initiation of dialysis?. Kidney Int 58 (2000) 1381-1388
15. Korevaar J., Jansen M., Dekker F., et al. Evaluation of DOQI guidelines: Early start of dialysis is not associated with better health-related quality of life. Am J Kidney Dis 39 (2002) 108-115
16. Hou F., Zhang X., Zhang G.H., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354 (2006) 131-140
17. Weiner D.E., Tighiouart H., Amin M.G., et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol 15 (2004) 1307-1315
18. Sarnak M.J., Levey A.S., Schollweth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease. Circulation 108 (2003) 2154-2169
19. Muntner P., He J., Hamm L., et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13 (2002) 745-753
20. Jurkowitz C.T., Abramson J.L., Vaccarino L.V., et al. Association of high serum creatinine and anemia increases the risk of coronary events: Results from the prospective community-based Atherosclerosis Risk in Communities (ARIC) study. J Am Soc Nephrol 14 (2003) 2919-2925
21. Kidney Early Evaluation Program (KEEP). Annual Data Report-2004. Am J Kidney Dis 45 suppl 2 (2005) 1-135
22. Clyne N., and Jogestrand T. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 60 (1992) 390-396
23. Lim V.S., Degowin R.L., Zavala D., et al. Recombinant human erythropoietin treatment in predialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 110 (1989) 108-114
24. Revicki D.A., Brown R.E., Feeny D.H., et al. Health-related quality of life associated with recombinant human erythropoietin for predialysis chronic renal disease patients. Am J Kidney Dis 25 (1995) 558-564
25. Kuriyama S., Tomonari H., Yoshida H., et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77 (1997) 176-185
26. Roth D., Smith D., Schulman G., et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24 (1994) 777-784
27. Jungers P., Choukroun G., Oualim Z., et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16 (2001) 307-312
28. Eknoyan G. The importance of early treatment of the anaemia of chronic disease. Nephrol Dial Transplant 16 suppl 5 (2001) 45-49
29. Becker B., Becker Y., Leverson G., et al. Erythropoietin therapy may retard progression in chronic renal transplant dysfunction. Nephrol Dial Transplant 17 (2002) 1667-1673
30. Silverberg D., Wexler D., Blum M., et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18 (2003) 141-146
31. Gouva C., Nikolopoulos P., Ioannidis J.P.A., et al. Treating anemia early in renal failure patients slows the decline of renal function: A randomized control trial. Kidney Int 66 (2004) 753-760
32. Rossert J., Fouqueray B., and Boffa J.J. Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol 14 (2003) S173-S177
33. Hsu C.Y., Lin F., Vittinghoff E., et al. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 14 (2003) 2902-2907
34. Brown W.W., Collins A., Chen S.C., et al. Identification of persons at high risk for kidney disease via targeted screening: the NKF Kidney Early Evaluation Program. Kidney Int 83 (2003) S50-S55
35. Warnock D.G., McClellan W., McClure L.A., et al. Prevalence of chronic kidney disease and anemia among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study: Baseline results. Kidney Int 68 (2005) 1427-1431
36. Provenzano R., Bhaduri S., Singh A.K., and PROMPT Study Group. Extended epoietin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clin Nephrol 64 (2005) 113-123
37. US Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States (2005), National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD